NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
ICRA Reaffirms Biocon's AA+ Rating; Highlights $1.17B Biocon Biologics Consolidation
ICRA has reaffirmed Biocon's credit rating at [ICRA]AA+ (Stable) following the company's announcement to acquire the remaining minority stakes in Biocon Biologics (BBL) for $1.17 billion. The transaction involves a $773 million share swap and a $400 million cash component, funded through Commercial Paper and a proposed Rs. 4,500 crore QIP. This move simplifies the group structure, making BBL—which accounts for 58% of FY25 revenues—a wholly-owned subsidiary. While consolidated leverage is expected to reduce after repaying structured debt by January 2026, the successful execution of the QIP remains a key monitorable factor.
முக்கிய அம்சங்கள்
ICRA reaffirmed [ICRA]AA+ (Stable) and [ICRA]A1+ ratings for Rs. 450 crore unallocated limits.Biocon to acquire minority stakes in Biocon Biologics for $1.17 billion, making it a 100% subsidiary.Funding includes a Rs. 6,950 crore share swap and a $400 million cash payment.Company plans a QIP of up to Rs. 4,500 crore to repay bridge financing and structured debt by Jan 2026.Biocon Biologics is the largest revenue contributor, accounting for 58% of consolidated FY25 revenue.
👀 கவனிக்க வேண்டியவை
Investors should monitor the successful completion of the Rs. 4,500 crore QIP as it is crucial for deleveraging the balance sheet. The consolidation of the biologics business is a strategic positive that eliminates holding company discounts and simplifies the corporate structure.
BIL Vyapar Ltd (Binani Industries) Schedules Committee of Creditors Meeting for Dec 19, 2025
BIL Vyapar Limited, formerly known as Binani Industries Limited, has scheduled a meeting of its Committee of Creditors (CoC) for December 19, 2025. This follows the initiation of the Corporate Insolvency Resolution Process (CIRP) by the NCLT via an order dated November 13, 2025. The company's management and assets are currently under the control of Interim Resolution Professional (IRP) Subodh Kumar Agrawal. This meeting is a critical step in the insolvency process to determine the company's future resolution or liquidation path.
முக்கிய அம்சங்கள்
Committee of Creditors (CoC) meeting scheduled for December 19, 2025Company placed under Corporate Insolvency Resolution Process (CIRP) effective November 13, 2025Affairs and assets are being managed by IRP Subodh Kumar Agrawal (Reg No: IBBI/IPA-001/IP-P00087/2017-18/10183)Disclosure made under Regulation 30 of SEBI (LODR) Regulations, 2015NCLT order for insolvency was received by the company on November 21, 2025
👀 கவனிக்க வேண்டியவை
Investors should exercise extreme caution as equity value is typically significantly diluted or wiped out during insolvency proceedings. Monitor the CoC meeting outcomes for any proposed resolution plans or potential liquidation updates.
SBI Appoints Ravi Ranjan as Managing Director Effective Dec 15, 2025
State Bank of India (SBIN) announced the appointment of Shri Ravi Ranjan as Managing Director, effective December 15, 2025. He will hold the position until his superannuation on September 30, 2028, or until further orders. Shri Ranjan was previously Deputy Managing Director and is responsible for Risk, Compliance, & Stressed Assets Resolution Group. He joined the bank as Probationary Officer in 1991 and has over 34 years of experience.
முக்கிய அம்சங்கள்
Shri Ravi Ranjan appointed as Managing Director effective December 15, 2025.Term of appointment is until September 30, 2028 (superannuation) or until further orders.Shri Ravi Ranjan has over 34 years of experience in banking and finance since 1991.
👀 கவனிக்க வேண்டியவை
Investors should note the change in leadership and monitor Shri Ranjan's strategic initiatives in Risk, Compliance, and Stressed Assets Resolution. No immediate action is required.
Panacea Biotec: CFO Appointment, Company Secretary Change & Policy Revision
Panacea Biotec has announced key management changes. Mr. Vinod Goel, currently Group CFO, is appointed as CFO effective December 16, 2025, succeeding Mr. Devender Gupta. Consequently, Mr. Goel will cease to be the Company Secretary. Mr. Ankit Jain is appointed as Company Secretary and Compliance Officer from December 16, 2025. The board also adopted a revised policy for determining the Materiality of Events.
முக்கிய அம்சங்கள்
Mr. Vinod Goel appointed as Group Chief Financial Officer and Head Legal & Corporate Governance w.e.f. December 16, 2025.Mr. Ankit Jain appointed as General Manager – Legal & Company Secretary w.e.f. December 16, 2025.Mr. Vinod Goel has over 35 years of post-qualification experience.Mr. Ankit Jain has around 15 years of experience in corporate governance and regulatory compliance.Revised Policy for determining Materiality of Events / Information effective December 16, 2025.
👀 கவனிக்க வேண்டியவை
Investors should note the changes in key management personnel. Monitor future filings for any impact from the revised policy on materiality of events.
Panacea Biotec appoints Ankit Jain as Company Secretary w.e.f. Dec 16, 2025
Panacea Biotec Limited announced the appointment of Mr. Ankit Jain as the Company Secretary & Compliance Officer, effective December 16, 2025. This follows the cessation of Mr. Vinod Goel from the role of Company Secretary and Compliance Officer on December 15, 2025, due to his appointment as Group CFO. Mr. Jain, aged about 38 years, previously served as Assistant General Manager - Legal of the company’s wholly owned subsidiary, Panacea Biotec Pharma Ltd. The board also revised the policy for determining materiality of events and authorized key managerial personnel for disclosures.
முக்கிய அம்சங்கள்
Ankit Jain appointed as Company Secretary & Compliance Officer w.e.f. December 16, 2025Vinod Goel appointed as Group CFO and Head Legal & Corporate Governance w.e.f. December 16, 2025Vinod Goel ceases to be Company Secretary and Compliance Officer w.e.f. December 15, 2025Ankit Jain has around 15 years of experience in corporate governanceBoard meeting concluded at 03:36 P.M. on December 15, 2025
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's filings and announcements for further updates on key managerial personnel changes and strategic direction. No immediate action is required.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Panacea Biotec appoints Vinod Goel as CFO, effective Dec 16, 2025
Panacea Biotec has appointed Mr. Vinod Goel as the Chief Financial Officer (CFO) with effect from December 16, 2025. Mr. Goel, who is currently the Group CFO and Head Legal & Company Secretary, will now be designated as Group Chief Financial Officer and Head Legal & Corporate Governance. This follows the resignation of Mr. Devender Gupta from the CFO position, effective December 15, 2025. Mr. Ankit Jain has been appointed as Company Secretary and Compliance Officer with effect from December 16, 2025.
முக்கிய அம்சங்கள்
Mr. Vinod Goel appointed as CFO w.e.f. December 16, 2025Mr. Ankit Jain appointed as Company Secretary w.e.f. December 16, 2025Mr. Vinod Goel has over 35 years of post-qualification experienceMr. Ankit Jain has around 15 years of experience
👀 கவனிக்க வேண்டியவை
The appointment of a new CFO and Company Secretary is a routine management change. Investors should monitor the company's performance under the new leadership.
SBI to sign EURO 150 million Line of Credit with KfW
State Bank of India (SBI) will be signing a EURO 150 million Line of Credit with KfW (German Development bank). This credit line is dedicated to financing Climate Friendly Energy Generation projects. The signing is scheduled for December 16, 2025, at KfW Headquarters Frankfurt. This initiative indicates SBI's commitment to sustainable financing and could enhance its reputation among environmentally conscious investors.
முக்கிய அம்சங்கள்
SBI to sign EURO 150 million Line of Credit with KfWLine of Credit is for financing Climate Friendly Energy Generation projectsSigning scheduled on 16.12.2025 at KfW Headquarters Frankfurt
👀 கவனிக்க வேண்டியவை
Investors should note SBI's increasing focus on green financing, which could positively impact its long-term sustainability and attract ESG-focused investments. Monitor the deployment and impact of this EURO 150 million credit line on SBI's financials and environmental footprint.
MobiKwik Q2 FY26: EBITDA Losses Narrow by 80% QoQ; Contribution Profit Up 24%
One MobiKwik Systems Limited reported a strong operational recovery in Q2 FY26, with EBITDA losses narrowing significantly to INR 64 Mn from INR 312 Mn in Q1 FY26. While total income remained steady at INR 2,793 Mn, contribution profit rose 24% QoQ to INR 961 Mn, driven by a 10% reduction in direct costs and a 5.7% reduction in fixed costs. The payments business achieved a record GMV of INR 432 Bn (up 53% YoY), and financial services gross margins rebounded sharply to 41.8% from 13.3% in the previous quarter.
முக்கிய அம்சங்கள்
EBITDA loss narrowed by 80% QoQ to INR 64 Mn, moving the company closer to breakeven.Payments GMV grew 53% YoY to reach a record INR 432 Bn in Q2 FY26.Financial Services Gross Margin surged to 41.8% from 13.3% QoQ as lending costs normalized.Registered user base reached 183.5 Mn, reflecting a 9.9% YoY growth with 3.3 Mn new users added in Q2.Direct costs were optimized by 10% QoQ, while fixed costs decreased by 5.7% to INR 1,025 Mn.
👀 கவனிக்க வேண்டியவை
Investors should view the sharp reduction in EBITDA losses and the recovery in financial services margins as a positive sign of the company's path to profitability. Monitor the sustainability of cost-cutting measures and the growth of the UPI and FX Retail segments in upcoming quarters.
Aditya Birla Money Extends Preference Share Redemption to 2026; Total Value ₹109.99 Cr
Aditya Birla Money has approved a one-year extension for the redemption of 16,00,000 preference shares held by its promoter, Aditya Birla Capital. The redemption date is moved from December 2025 to December 2026, providing short-term liquidity relief. However, the redemption price per share has been increased from ₹639 to ₹687.44 to compensate for the delay. This adjustment raises the total redemption obligation from ₹102.24 crore to ₹109.99 crore.
முக்கிய அம்சங்கள்
Extension of 16,00,000 preference shares redemption period by 1 year to Dec 23, 2026Redemption price per share revised upward from ₹639 to ₹687.44Total redemption liability increased from ₹102.24 crore to ₹109.99 croreApproval of modifications to Material Related Party Transactions with Aditya Birla Capital
👀 கவனிக்க வேண்டியவை
The extension preserves immediate cash but increases the eventual payout; investors should watch for the impact on the company's balance sheet in late 2026.
Biocon launches Liraglutide (gVictoza®) in Netherlands
Biocon Limited has launched its Glucagon-like Peptide-1 (GLP -1), Liraglutide, in the Netherlands through its distribution partner Pharmamedic B.V. The drug-device combination will be marketed under the brand names Diavorin® for diabetes and Vobexoryn® for chronic weight management. This launch marks the first country in the European Union where Biocon will directly launch Liraglutide under its own brand. Liraglutide was approved for medical use in the European Union in 2009.
முக்கிய அம்சங்கள்
Biocon launched Liraglutide in the Netherlands on December 15, 2025.Liraglutide will be marketed as Diavorin® for diabetes.Liraglutide will be marketed as Vobexoryn® for chronic weight management.Liraglutide was approved for medical use in the European Union in 2009.
👀 கவனிக்க வேண்டியவை
This launch in the Netherlands is a positive step for Biocon, indicating expansion in the European market; investors should monitor the sales performance of Diavorin® and Vobexoryn® in the coming quarters.
Biocon Biologics to Commercialize Biosimilar Aflibercept Worldwide
Biocon Biologics has signed a settlement and license agreement to commercialize biosimilar Aflibercept (YESAFILI) worldwide. This agreement with Regeneron and Bayer covers Europe and the rest of the world, following a previous settlement for the US and Canada. YESAFILI is a VEGF inhibitor used for ophthalmology conditions. The company plans to launch YESAFILI in the UK in January 2026 and in other settled countries by March 2026 or earlier.
முக்கிய அம்சங்கள்
Biocon Biologics will commercialize biosimilar Aflibercept (40mg/ml) worldwide.YESAFILI launch in the United Kingdom is planned for January 2026.YESAFILI launch in other settled countries is planned for March 2026 or earlier.Biocon Biologics has commercialized 10 biosimilars across 120+ countries.
👀 கவனிக்க வேண்டியவை
This agreement expands Biocon Biologics' global presence in the ophthalmology therapeutic area. Investors should monitor the launch and market uptake of YESAFILI in 2026.
IFB Industries' wholly-owned subsidiary, Global Automotive & Appliances Pte. Ltd. (GAAL), has incorporated a new step-down subsidiary in Switzerland named Schmid Automotive & Appliances GmbH. The new entity has a paid-up share capital of CHF 20,000, consisting of 2,000 shares at CHF 10 each. This subsidiary is established to focus on the design, development, and planning of machine tools and fine blanking tools to enhance the company's overall engineering capabilities. As a newly formed entity, it has not yet commenced business operations and reports nil turnover.
முக்கிய அம்சங்கள்
Incorporation of Schmid Automotive & Appliances GmbH in Switzerland on December 10, 2025.100% ownership held by IFB's subsidiary GAAL, making it a step-down subsidiary of IFB Industries.Initial paid-up share capital of CHF 20,000 (2,000 shares of CHF 10 each).Strategic focus on R&D and engineering for machine tools and fine blanking tools.The entity is currently in the pre-operational stage with no reported turnover yet.
👀 கவனிக்க வேண்டியவை
Investors should monitor how this Swiss-based engineering hub contributes to IFB's product development and technical capabilities in the long term. While the immediate financial impact is negligible, it strengthens the company's strategic positioning in the automotive and appliance industries.
SBIN to invest ₹1 Crore in Indian Digital Payment Intelligence Corporation
State Bank of India (SBIN) has received RBI approval to establish a Section 8 company under the Companies Act, 2013. SBIN will subscribe to 1,00,00,000 (One crore) equity shares of Indian Digital Payment Intelligence Corporation (IDPIC) as the initial promoter. The investment will be at a face value of ₹10 per share, acquiring a 50% stake in the company. This move signifies SBIN's strategic interest in the digital payment intelligence space.
முக்கிய அம்சங்கள்
RBI approved SBIN to establish a Section 8 company.SBIN to invest ₹1 Crore in IDPIC.SBIN will acquire a 50% stake in IDPIC.The face value of each share is ₹10.
👀 கவனிக்க வேண்டியவை
Investors should monitor the performance of this new venture and its impact on SBIN's overall digital strategy. Keep an eye on further developments related to IDPIC and its role in the digital payment ecosystem.
S&P Global Places Biocon Biologics on Positive CreditWatch; Debt to Drop to ₹120 Billion
S&P Global Ratings has placed Biocon Biologics on 'CreditWatch Positive' following a major restructuring plan to make it a 100% subsidiary of Biocon Limited. The company aims to reduce its adjusted debt significantly from INR 248 billion in March 2025 to approximately INR 120 billion by March 2026. This reduction will be driven by swapping $1 billion in debt-like CCPS held by Viatris for equity and cash, alongside a planned INR 45 billion fresh equity issuance. The move simplifies the capital structure and eliminates minority put options that were previously viewed as debt-like obligations.
முக்கிய அம்சங்கள்
S&P Global placed 'BB' rating on CreditWatch Positive, signaling a potential upgrade within 60-90 days.Adjusted debt is projected to fall by over 50% to INR 120 billion by the end of FY26.Biocon to acquire the remaining 25% stake in Biocon Biologics from minority investors including Viatris and Serum Institute.Viatris' $1 billion CCPS will be settled through $415 million in Biocon equity and $400 million in cash.The cash component for the transaction is intended to be funded via a fresh INR 45 billion equity raise.
👀 கவனிக்க வேண்டியவை
Investors should view this as a major positive for the balance sheet as it significantly reduces leverage and simplifies the corporate structure. Key monitorables include the successful execution of the INR 45 billion equity fundraise and the final resolution of the CreditWatch by S&P.
Tasty Bite Q2 FY25 PAT Rises 24% YoY to ₹96.1 Million; Revenue Up 14.6%
Tasty Bite Eatables Limited reported a strong performance for the quarter ended September 30, 2025, with revenue from operations increasing 14.6% YoY to ₹1,328.67 million. Net profit for the quarter grew significantly by 23.9% YoY to ₹96.14 million, up from ₹77.58 million in the previous year. For the first half of FY25, the company achieved a PAT of ₹188.34 million compared to ₹153.27 million in H1 FY24. Additionally, the company strengthened its governance by appointing KPMG as internal auditors and adding Hans Bakker to the Board.
முக்கிய அம்சங்கள்
Revenue from operations grew 14.6% YoY to ₹1,328.67 million in Q2 FY25.Net Profit (PAT) increased by 23.9% YoY to ₹96.14 million for the quarter.Earnings Per Share (EPS) rose to ₹37.47 from ₹30.23 in the corresponding quarter last year.Cash and cash equivalents surged to ₹577.64 million as of September 30, 2025, from ₹153.48 million in March 2025.H1 FY25 total income reached ₹2,592.17 million, a 10.9% increase over H1 FY24.
👀 கவனிக்க வேண்டியவை
Investors should view the consistent top-line and bottom-line growth positively, alongside the significantly improved cash position. The stock remains a key play in the 'Prepared Foods' segment, though monitoring raw material price volatility is advised.
MobiKwik: Top 3 Fastest-Growing UPI App, 3x YoY Growth in Oct '25
MobiKwik has announced that it is among the top 3 fastest-growing UPI apps in India in Q2FY26. The company's UPI transactions surged 38% QoQ, and UPI GMV increased by 28%. MobiKwik also registered 3x YoY UPI growth in October 2025. Pocket UPI is emerging as a key driver of MobiKwik’s UPI scale, allowing users to make UPI payments directly from their MobiKwik Wallet.
முக்கிய அம்சங்கள்
UPI transactions surged 38% QoQUPI GMV increased by 28%Registered 3x YoY UPI growth in October 2025MobiKwik has a 19% market share of the PPI wallet gross transaction value (GTV) as of September 2025Serving 183.5 Mn+ registered users and 4.71 Mn+ merchants
👀 கவனிக்க வேண்டியவை
Investors should monitor MobiKwik's ability to sustain this growth and improve profitability. Watch for further updates on user acquisition and engagement metrics.
SAT Upholds IRDAI Order for Transfer of Sahara Life Assets and Liabilities to SBI Life
The Securities Appellate Tribunal (SAT) has dismissed an appeal by Sahara India Life Insurance (SILIC) against a 2023 IRDAI order. This ruling mandates the immediate transfer of all SILIC policyholder-related assets and liabilities to SBI Life Insurance Company Limited. The decision, received on December 10, 2025, concludes a legal challenge to the IRDAI's directive aimed at protecting Sahara's policyholders. This transfer will result in an inorganic expansion of SBI Life's policyholder base and assets under management.
முக்கிய அம்சங்கள்
SAT dismissed the appeal filed by Sahara India Life Insurance against the IRDAI order dated June 2, 2023.SBI Life is directed to immediately take over all policyholder-related assets and liabilities of SILIC.The order follows a multi-year regulatory effort to safeguard the interests of Sahara Life policyholders.The transfer is expected to increase SBI Life's market share and total policyholder liabilities under management.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive development that reinforces SBI Life's role as a stable market leader. Monitor for upcoming disclosures regarding the specific financial impact on the company's Embedded Value and integration costs.
SBI Receives RBI Approval to Set Up Digital Payments Intelligence Platform
State Bank of India (SBI) has received approval from the Reserve Bank of India (RBI) to establish a Section 8 company named Indian Digital Payment Intelligence Corporation. This new entity will focus on creating a Digital Payments Intelligence Platform to enhance the security and monitoring of digital transactions. The Department of Financial Services has granted a specific exemption allowing SBI to hold more than 30% of the paid-up share capital in this company. This exemption from Section 19(2) of the Banking Regulation Act is currently valid until October 16, 2026.
முக்கிய அம்சங்கள்
RBI approval granted to establish 'Indian Digital Payment Intelligence Corporation' as a Section 8 company.Exemption received from Section 19(2) of the Banking Regulation Act, 1949, to hold over 30% stake.The shareholding exemption for the proposed entity is valid until October 16, 2026.The platform is designed to provide intelligence and risk management for the digital payments ecosystem.The initiative aligns with national goals to reduce digital payment frauds and improve transaction security.
👀 கவனிக்க வேண்டியவை
Investors should view this as a strategic move to strengthen SBI's digital infrastructure and risk management capabilities. While not a direct profit driver, it reinforces SBI's leadership in the digital banking space and long-term operational stability.
India Ratings has assigned 'IND AA+/Stable/IND A1+' to Biocon's bank loan facilities of INR 5,500 million and 'IND A1+' to proposed commercial paper of INR 8,000 million. The agency has also affirmed 'IND AA+/Stable/ IND A1+' for existing bank loan facilities of INR 4,500 million and 'IND A1+' for proposed commercial paper of INR 12,000 million. The rating on non-convertible debentures of INR 10,700 million has been withdrawn as the instrument has been paid in full. These ratings reflect India Ratings' assessment of Biocon's creditworthiness.
முக்கிய அம்சங்கள்
INR 5,500 million bank loan facilities assigned IND AA+/Stable/IND A1+ ratingINR 8,000 million proposed commercial paper assigned IND A1+ ratingINR 4,500 million bank loan facilities affirmed at IND AA+/Stable/ IND A1+INR 12,000 million proposed commercial paper affirmed at IND A1+INR 10,700 million non convertible debenture rating withdrawn
👀 கவனிக்க வேண்டியவை
Investors should monitor Biocon's debt levels and credit ratings for any changes. The affirmed and assigned ratings indicate a stable outlook for the company's debt obligations.
Biocon to Consolidate 100% Stake in Biocon Biologics via $1.17 Billion Deal
Biocon Limited has announced a major consolidation plan to acquire the remaining 23.3% minority stake in Biocon Biologics, making it a 100% subsidiary. The transaction involves a $773 million share swap (171.3 million shares at ₹405.78 each) and a $400 million cash payment to Viatris. This move is designed to simplify the corporate structure, eliminate the holding company discount, and improve financial metrics, with a proforma Net Debt/EBITDA ratio of 2.5x. The company expects the transaction to be completed by Q4 FY2026, following a shareholder vote on December 31, 2025.
முக்கிய அம்சங்கள்
Acquisition of 23.3% minority stake from Viatris, Serum Institute, Tata Capital, and True North.Total consideration includes $773M in equity shares and $400M in cash funded via QIP or bridge loans.Consolidation expected to generate annual interest savings of ₹300 crore.Proforma Net Debt/EBITDA reduced to 2.5x from 4.3x in FY23 through deleveraging and EBITDA growth.Targeting transaction completion by Q4 FY2026 with a long-stop date of March 31, 2026.
👀 கவனிக்க வேண்டியவை
Investors should look favorably on this consolidation as it simplifies the group structure and removes the holding company discount. Monitor the upcoming EGM on December 31 and the successful execution of the $400M cash funding through a QIP or rights issue.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
